Introduction
Stimulation of cells with insulin results in activation of multiple signal transduction pathways regulating such diverse processes as proliferation, dierentiation, glucose transport and glycogen metabolism. In MCF7 human breast cancer cells mitogenic stimulation with insulin or insulin-like growth factor-I (IGF-I) leads to induction of c-jun and c-fos (van der Burg et al., 1989; 1990a; Philips et al., 1993) . Little is known about the mechanisms by which the regulation of these protooncogenes occurs in these cells, and their role in the mitogenic response is still obscure. An important step in insulin signaling is activation of the GTP binding protein Ras. This is followed by a cascade of phosphorylation reactions involving Raf, MEK1 and the MAP kinases Erk1/2 (Marshall, 1994; Cobb and Goldsmith, 1995) , a seemingly major step in mitogenic signaling (Meloche et al., 1992; PageÁ s et al., 1993) . The duration of MAP kinase activity is important in determining the cellular response. Prolonged activation of the MAP kinase pathway may play a role in cell proliferation as well as in dierentiation, depending on the cell type. For instance, in PC12 cells dierentiation by NGF is the result of prolonged MAP kinase activation, whereas EGF stimulates transient MAP kinase activation accompanied by a mitogenic response (Marshall, 1995; Pang et al., 1995) . MAP kinases act in the nucleus by phosphorylating and thereby activating several transcription factors, thereby directly or indirectly in¯uencing AP1-constituents (Hill and Treisman, 1995; Karin, 1995; Su and Karin, 1996) .
The transcription factor AP1 consists of homodimers of Jun proteins or heterodimers of Jun with Fos or CREB/ATF family members and is induced by a large number of stimuli, including growth factors. Its formation has been found to be important in transducing mitogenic signals (Angel and Karin, 1991) , and inhibition of AP1 activity generally leads to impaired mitogenesis and reduced malignant transformation (Kovary and Bravo, 1991; Brach et al., 1993; Johnson et al., 1993; Schlingensiepen et al., 1993; Domann et al., 1994; Mayo et al., 1994) . Evidence has been presented that the MAP kinases directly phosphorylate and thereby stimulate transcriptional activity of pre-existing c-Jun protein (Pulverer et al., 1991) , and it has become clear that this phosphorylation is mediated by the Jun N-terminal kinase (JNK) subgroup of MAP kinases (Hibi et al., 1993; Minden et al., 1994) . This will lead to enhanced transcription of c-jun itself through an autoregulatory AP1 binding site (also known as TRE for TPAresponsive element) in its promoter (Angel et al., 1988) . In addition, the serum response element (SRE), present in the c-fos and junB promoters, is recognized by the serum response factor (SRF), whose binding results in recruitment of the ternary complex factor (TCF). Phosphorylation of the TCF proteins Elk-1 and SAP-1 by Erk (Gille et al., 1993) leads to increased transcriptional activity on the SRE (Treisman, 1994; Hill and Treisman, 1995) .
The induction of AP1 constituents can be observed after challenging cells with either mitogens or antiproliferative agents (Bartel et al., 1989; Pertovaara et al., 1989; de Groot and Kruijer, 1991; Alkhalaf and Murphy, 1992; Hashimoto et al., 1993) . Often growth inhibition is accompanied by dierentiation of the AP1 expressing cells (Bartel et al., 1989; de Groot et al., 1990; de Groot and Kruijer, 1991) . The fact that AP1 is involved in such divergent cellular responses suggests that it is an important switch in intracellular signaling. Possibly, the composition of the AP1 dimer may be important in this respect, since it has been found that dierent complexes have distinct DNA binding properties (Ryseck and Bravo, 1991) . In particular, JunB has been found to be a relatively poor DNA binder, that prefers multimeric DNA elements and preferentially forms heterodimers with c-Jun or Fos proteins (Ryseck and Bravo, 1991; Deng and Karin, 1993) . JunB can inhibit c-Jun mediated transactivation through single AP1 binding sites (Chiu et al., 1989; SchuÈ tte et al., 1989) and can also repress transformation of rat embryo ®broblasts by c-Jun (SchuÈ tte et al., 1989) . Although JunB and c-Jun often are co-expressed in cell lines dierential expression of these genes has also been found (Bartel et al., 1989; Redner et al., 1992; Melamed et al., 1993; Nishina et al., 1993; Su et al., 1994) . Expression of c-Jun seems important for proliferation (Kovary and Bravo, 1991; Brach et al., 1993; Johnson et al., 1993; Schlingensiepen et al., 1993; Mayo et al., 1994) , although in some cell types a role in dierentiation has been reported (de Groot et al., 1990; de Groot and Kruijer, 1991) . Expression of JunB is induced by various growth inhibitors and may functionally be linked to growth inhibition and dierentiation (Schlingensiepen et al., 1993) , which is in line with the opposing actions of c-Jun and JunB.
Whereas proliferation of MCF7 cells is stimulated by insulin, the phorbol ester TPA induces growth arrest accompanied by dierentiation in these cells (Abe and Kufe, 1986; Valette et al., 1987) . TPA can stimulate proliferation and transformation of cells by activating PKC followed by Raf-MEK-MAP kinase activation. We have used these opposing abilities of insulin and TPA to study activation of the MAP kinases Erk2 and JNK to see whether dierential regulation of these pathways may explain some of the cellular eects. We show that the duration of Erk2 activity is inversely correlated with mitogenic signaling. As a result of prolonged Erk activation, SREdependent transcriptional activity is high in MCF7 cells. This causes a strong induction of junB by growth inhibitor TPA, whereas the mitogen insulin predominantly induces c-jun, correlating with activation of JNK. Inhibition of the Erk pathway does not in¯uence mitogenicity of insulin and furthermore can alleviate the inhibitory action of TPA on S-phase entry.
Results
Insulin and TPA have opposite eects on G 1 transition of MCF7 cells
Growth factor-deprived MCF7 cells become quiescent in the G 1 /G 0 -phase of the cell cycle, whereas they reenter the cell cycle when stimulated with insulin or insulin-like growth factor-I (IGF-I) (van der Burg et al., 1988; 1990b) . MCF7 cells have been found to be highly sensitive to growth inhibition by phorbol esters. Figure 1a and b show that MCF7 cell proliferation is stimulated by insulin but strongly inhibited by simultaneous addition of TPA. Maximal inhibition by TPA is attained at concentrations of 1 ng/ml and higher. [ Figure 1c ). To reach optimal levels of DNA synthesis, insulin has to be present during almost the entire G 1 period, but not during the subsequent S-phase ( Figure 1d ). In addition, TPA eciently blocks DNA synthesis when added to insulin-stimulated cells during the ®rst 12 h of the G 1 period. However, its eectiveness rapidly declines when added a few hours before entry into the S-phase ( Figure 1d ). This suggests that insulin-induced critical events necessary for cell cycle progression occur during almost the entire G 1 period and that TPA is able to aect these processes negatively.
Prolonged activation of Erk2 by TPA but not by insulin
Erk1 and 2 can be activated by TPA and insulin in many cell types. Prolonged activation of Erks is often correlated with cell cycle progression. As insulin and TPA clearly have opposite eects on MCF7 cell proliferation, we have investigated whether this is due to dierential activation of MAP kinases. Figure 2a shows a mobility shift assay of p42 MAPK (Erk-2) in MCF7 cells stimulated with TPA or insulin in a timecourse experiment. Surprisingly, a strong and longlasting (46 h) activation of Erk2 is induced by the growth inhibitor TPA, whereas insulin gives a modest and transient (530 min) activation of Erk2. In comparison, stimulation of the cells with epidermal growth factor (EGF) results in an almost complete but transient Erk2 shift (Figure 2b ), similar to that evoked by insulin. EGF has only a slight stimulatory eect on S-phase entry of these cells when compared with insulin. These results make it unlikely that mitogenic stimulation by insulin is accounted for by activation of Erks and probably involves (an)other signaling pathway(s). Furthermore, a prolonged activation of Erk2 does not correlate with mitogenicity in these cells.
In order to be able to manipulate the MAP kinase pathway, we used a speci®c inhibitor of the upstream kinase MEK1, named PD98059 (Dudley et al., 1995) . Figure 2c shows the eective inhibition of insulin-or TPA-induced Erk2 activation at dierent concentrations of PD98059.
JunB and c-jun are dierentially induced by insulin and TPA in late but not in early G 1
We studied the expression of immediate early genes cfos, c-jun and junB, as in many cells transcription of these genes is mediated by MAP kinases. The expression of c-fos and c-jun family members after stimulation of MCF7 cells with insulin or TPA is shown in Figure 3 . Despite their very dierent eects on proliferation, there is less obvious dierence in induction of c-fos, c-jun and junB mRNA after 30 min of stimulation by insulin, TPA or EGF, apart from a relatively strong c-fos induction by TPA. After 90 min of stimulation, however, TPA preferentially induces cfos and junB while in insulin-treated cells more c-jun than junB is detected. No other family member is dierentially induced; junD mRNA is constitutively expressed, while no expression of fra-1 and -2 or fosB mRNA can be detected (data not shown). The Northern blot in Figure 4 shows that after stimulation for more than 30 min the preferential induction of junB by TPA and, though much less pronounced, c-jun by insulin remains apparent for up to 8 h. A quantitation of c-jun and junB messengers is shown in Figure 6 . Cells were stimulated for the indicated periods of time with TPA (100 ng/ml), insulin (10 mg/ml) or EGF (10 ng/ml) and lysed in SDS-sample buer. p42 MAPK was visualized on Western blots using a rabbit polyclonal antiserum. The slower migrating band represents phosphorylated Erk2. (c) The MEK1-inhibitor PD98059 (New England Biolabs) was added 1 h prior to stimulation of the cells with TPA (100 ng/ml, 5 min) or insulin (10 mg/ml, 5 min)
At the protein level ( Figure 5 ), most striking dierences are observed at the levels of JunB: no JunB induction by insulin is detectable, whereas TPAstimulation leads to a clear induction that lasts for at least 24 h. The protein levels of c-Jun are induced by insulin as well as by TPA.
TPA-mediated induction of junB is dependent on Erk2
We used the speci®c MEK1-inhibitor PD98059 to investigate whether the dierential eects of insulin and TPA on expression of jun family members re¯ect the duration of their respective Erk2 activation. Figure 6 shows that the use of PD98059 prevents to a large extent the induction of junB mRNA by TPA, especially after stimulation of the cells for more than 2 h.
The levels of insulin-induced c-jun mRNA are not reduced in the presence of PD98059. As the insulinmediated Erk2 shift is fully inhibited at a concentration of 20 mM of PD98059, these results suggest that the prolonged induction of c-jun as detected after insulinstimulation is not regulated via the MAP kinases of the Erk subgroup but via an alternative route. The strong induction of JunB by TPA, however, is the result of prolonged Erk2 activation and correlates with growth inhibition.
Also other immediate early genes, such as c-fos and egr-1, are strongly induced by TPA in these cells and appear to be Erk targets, since their transcription is inhibited by PD98059 (results not shown).
Insulin but not TPA activates JNK
As the JNK subgroup of MAP kinases plays a crucial role in activation of c-Jun, we determined its activity in an immune complex kinase assay. Stimulation of MCF7 cells with insulin results in activation of JNK (Figure 7 ) peaking after 30 min of stimulation. This correlates well with the observed increase in c-Jun mRNA by insulin, probably re¯ecting an autoregulatory function of c-Jun on its own promoter. In the same time-span, we found neglectable levels of JNK activation by TPA (Figure 7) , suggesting that the increase in c-jun mRNA after TPA-stimulation, as seen in Figure 4 , is regulated in a dierent manner.
Insulin and TPA activate TRE-and SRE-dependent reporter constructs
It has been described that in mouse embryonal carcinoma cells junB can transactivate only through multiple and not through single TREs (Chiu et al., 1989; SchuÈ tte et al., 1989) . We have tested whether the observed dierences in JNK activation and JunB expression result in a dierential transactivation of promoter constructs containing one or ®ve functional TREs linked to the chloramphenicol acetyl transferase (CAT) gene in transient transfections. TPA is less ecient than insulin in activating the 1xTRE containing construct (Figure 8a ), which is in accordance with the relatively poor induction of c-jun. In contrast, the 5xTRE containing construct is much stronger induced by TPA than by insulin (Figure 8a ), suggesting that this is due to the dierences in JunB levels induced.
The dierential eects of TPA and insulin on c-Jun and JunB expression are clearly the result of dierent signaling cascades, JunB being mediated by Erk activation. In other cell types junB induction by TPA has been reported to be largely mediated by a serum response element (SRE) located downstream of the , 1993) , whereas autoinduction via a single TRE mainly mediates induction of cjun (Angel et al., 1988) . Since insulin is a relatively strong activator of a single TRE containing construct (Figure 8a ), this may explain its ability to induce c-Jun expression. Consistent with the strong activation of JunB expression in MCF7 cells, TPA was found to be a very potent inducer of a 3xSRE containing reporter construct (Figure 8b ). Insulin on the other hand hardly yields SRE activation in MCF7 cells.
Reversion of TPA-induced growth inhibition and pRB phosphorylation by PD98059
To test the hypothesis that in MCF7 cells the growth inhibition by TPA is the result of prolonged activation of Erks, we used the MEK1-inhibitor PD98059 in a thymidine incorporation assay. Figure 9a shows the inhibitory eect of TPA on insulin-induced DNAsynthesis of quiescent MCF7 cells. In the presence of PD98059 (20 mM), TPA loses most of its ability to inhibit insulin-induced entry into S-phase, whereas DNA synthesis induced by insulin alone is marginally reduced. A hallmark of G 1 -S transition is the hyperphosphorylation of the retinoblastoma tumor suppressor protein (pRB). This allows transcription factors of the E2F family to become active and trigger expression of genes that enable cell cycle progression in the absence of growth factors (Sherr, 1996) . To investigate whether the TPA-induced inhibitory eects could be observed in late G 1 , we measured the phosphorylation state of pRB. Stimulation of the cells for 16 h with insulin yields a reduced mobility, re¯ecting hyperphosphorylation, of pRB (Figure 9b ). Simultaneous addition of TPA and insulin leads to a complete repression of pRB phosphorylation. In the presence of PD98059, however, TPA was no longer able to inhibit the induction of pRB phosphorylation by insulin. These results are in complete agreement with the observed eects of PD98059 on S-phase entry in Figure 9a . We conclude that prolonged activation of the Erk MAP kinases mediates strong growth inhibitory signals in MCF7 cells.
Discussion
Induction of early response genes, in particular those coding for AP1 constituents, is tightly linked to mitogenic stimulation by growth factors. Typically, the transcription of these genes is rapidly but transiently induced followed by a transient induction of protein expression. However, by microinjection of speci®c antibodies it has been demonstrated that AP1 constituents are required during the entire G 1 phase of the cell cycle, also in cells in which initial stimulation of transcription is much shorter (Kovary and Bravo, 1991) . This is consistent with mitogenic stimulation being linked to expression of c-Jun even during the G 1 /S-phase transition (Carter et al., 1991; Trejo et al., 1992) . In line with these studies we show here that also in breast cancer cells mitogenic stimulation correlates with prolonged c-Jun induction. We show that the c-Jun protein is present throughout the G 1 phase of the cell cycle up to a few hours before the onset of S-phase after which the requirement for insulin rapidly declines. It seems likely that enhancement of c-Jun transactivation is mediated through the recently identi®ed Jun kinases (JNK) (Hibi et al., 1993; Kyriakis et al., 1994) , which are also MAP kinase family members. They may be of major importance in this respect (Minden et al., 1994 ; Su Westwick et al., 1994) . Insulin was able to activate JNK in MCF7 cells, correlating with c-Jun activation and proliferative signaling.
We found that TPA, a potent growth inhibitor for MCF7 cells (Valette et al., 1987) , can repress cellular proliferation during the same period of the cell cycle when insulin is active. Interestingly, TPA-sensitivity of MCF7 cells was found to correlate with the induction of JunB. JunB is known to be able to oppose transformation and transactivation by c-Jun, probably due to preferential heterodimerization with c-Jun, thereby inhibiting DNA binding by c-Jun (Deng and Karin, 1993) . Little is known about genes involved in cell cycle progression that are targets of c-Jun and JunB. However, it has been found that the promoter of cyclin D1, a cyclin required for progression through G 1 in breast cancer cells (Lukas et al., 1994; Musgrove et al., 1994 ) is activated by c-Jun (Herber et al., 1994) .
A reported mechanism by which TPA represses MCF7 proliferation is by inhibition of estrogen receptor function (Doucas et al., 1991; Tzukerman et al., 1991) . However, we do not think that this mechanism is relevant in our studies since we assessed growth inhibition by TPA in the absence of estrogenic stimulation. The egr-1 gene product, whose induction pattern closely matches that of junB might be involved in TPA induced growth inhibition. Since egr-1 is an early response gene of which the expression often is associated with dierentiation of cells (Sukhatme et al., 1988; Kharbanda et al., 1994) , it is a candidate gene to cooperate with junB in TPA induced dierentiation of MCF7 cells.
A role for JunB in growth inhibition of mammary tumor cells has been proposed on the basis of earlier studies showing that an ecient reduction of JunB expression in SK-Br-3 breast cancer cells leads to enhanced proliferation (Schlingensiepen et al., 1993) . In addition, we found that TGFb treatment of MCF7 cells leads to induction of junB and not c-jun concomitant with growth inhibition (results not shown). However, further studies are required in which expression of c-Jun and JunB is modulated more directly in order to give more insight in their role in growth regulation of breast cancer cells.
A surprising ®nding in our study was the fact that insulin is able to strongly stimulate cellular proliferation without a major induction of Erk2 MAP kinase activity and subsequent SRE-dependent transcriptional activation, suggesting that this pathway is not a prerequisite for proliferation. This is further demonstrated by EGF, which activates Erk2 to an extent similar to insulin, but is not mitogenic. In contrast, the MCF7 dierentiation-inducing agent TPA (Valette et al., 1987) caused particularly strong Erk2 activation and SRE-dependent transcription, suggesting that this pathway is involved in dierentiation rather than proliferation of these cells. The SRE is bound by the serum response factor (SRF) and an accessory factor Elk-1, and in most cell types this complex is a major transcription factor regulating c-fos expression (Treisman, 1994) . Consistent with this we found a particularly strong c-fos induction concomitant with strong SRE-dependent transcription upon TPA treatment of MCF7 cells. Although the junB gene has a complex promoter structure in regulatory elements located both upstream and downstream of the gene, a downstream SRE in the junB gene has been found to be the most prominent regulatory sequence (PerezAlbuerne et al., 1993) . Therefore, we think that the strong SRE-dependent transcription upon TPA treatment of MCF7 cells may be an explanation for the marked JunB expression observed. This is in line with our recent observation that expression of egr-1, which is known to be regulated by SRE-dependent transcriptional activity (Qureshi et al., 1991; Rupprecht et al., 1993) , closely parallels junB induction, both of them being strongly stimulated by TPA in a MAPKdependent manner.
The highly speci®c MEK1 inhibitor PD98059 has been particularly useful to discriminate between the insulin-and TPA activated signaling pathways. Because no other substrates for MEK1 than Erk1/2 were found, all PD98059-sensitive gene induction can be attributed to the MAP kinases Erk1/2, and those genes are SRE-regulated genes. Using this inhibitor we have shown that c-jun and junB are induced by dierent signal transduction pathways. Furthermore, it has become clear that activation of the Erk2 pathway is certainly not enough to induce a mitogenic response in MCF7 cells. The duration of MAP kinase activity seems important in determining cell cycle progression. Similar to what is found for NGF stimulation in PC12 cells (Marshall, 1995; Pang et al., 1995; Pumiglia and Decker, 1997) , the prolonged activation of Erk2 by TPA is in these cells very likely the cause of dierentiation rather than proliferation.
Materials and methods

Cell culture
MCF7 cells were cultured in a 1 : 1 mixture of Dulbecco's modi®ed Eagle's medium and Ham's F12 medium (DF) supplemented with 5% fetal calf serum (FCS). Prior to experiments, cells were maintained for 24 h in phenol redfree, bicarbonate buered DF (Gibco), supplemented with 5% steroid-stripped serum (DCC-FCS). DCC-FCS was prepared by treating FCS by dextran coated charcoal to remove steroids, as described (van Zoelen et al., 1993) . Hereafter the cells were kept in phenol red-free serum-free DF containing 30 nM selenite, 10 mg/ml transferrin and 0.2% BSA for another 24 h. The eects of mitogens on cell proliferation was determined by measuring the DNA content per well 4 days after stimulation, as described (van der Burg et al., 1988) . Entry into S-phase of the cells was measured by [ 3 H] thymidine (1 mCi/ml) incorporation between 20 ± 26 h after stimulation. PD98059 was obtained from New England Biolabs.
Transfection and CAT Assays
The cells were transfected essentially as described before (van der Burg et al., 1990a) . In short, they were seeded in DF medium supplemented with 5% DCC-FCS in 6-well plates and the next day they were incubated for 6 h with calcium phosphate-precipitated plasmid DNAs. The plasmids used to determine TRE-and SRE-dependent transcriptional activity contained one or ®ve copies of a synthetic oligonucleotide containing the collagenase TRE (van der Burg et al., 1990a) or three copies of the c-fos SRE (donated by Dr W Kruijer) in pBL-CAT2 (Luckow and SchuÈ tz, 1987) , referred to as tk-CAT. The empty vector was used as a control. The pSG5-based expression plasmids with the c-jun or junB (obtained from Dr D Nathans) coding region inserted were provided by Dr W Kruijer. Directly after transfection the cells were washed, and the medium was replaced by fresh medium containing 5% DCC-FCS and the compounds to be tested. After 24 h the cells were harvested to determine CAT activity using thin layer chromatography. Quantitation was carried out with a phospho-imager (Molecular Dynamics).
RNA extraction and Northern blot analysis
MCF7 cells, made quiescent by mitogen-deprivation, were lysed in guanidine isothiocyanate, and total RNA was extracted with the method of Chomczynski and Sacchi (1987) . Northern blots were prepared and hybridized using standard methods, as described (van der Burg et al., 1990a) . Quantitation was carried out with a phosphoimager.
Western blotting
After stimulation of the cells, they were placed on ice, washed with ice-cold PBS, and lysed in SDS-sample buer. The samples were sheared, boiled and loaded on 10% polyacrylamide mini-gels or 10% acrylamide/0.1% bisacrylamide long gels for detection of Erk2 shift. After electrophoresis proteins were blotted onto Immobilon membranes (Millipore). The blots were incubated for 30 min in TBST (10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.05% Tween-20) containing 5% non-fat dried milk. The primary antibodies used were recognizing p42 MAPK (Erk-2) (1 : 5000, rabbit polyclonal serum kindly provided by Dr W H Moolenaar); c-Jun (Santa Cruz SC-45, 1 mg/ml); JunB (Santa Cruz SC-46, 2 mg/ml) or pRB (PharMingen, 0.1 mg/ml) and were diluted in the same buer. After 1 h incubation at room temperature the blots were washed in the above buer without milk, incubated with horseradish peroxidase conjugated goat anti-rabbit or goat anti-mouse (Amersham) and subsequently stained by the ECL procedure (Amersham).
Immune complex Jun kinase assay
Quiescent MCF7 cells (2x10 6 ) were challenged with various stimuli, washed with ice-cold PBS and lysed in: 25 mM HEPES pH 7.5, 300 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM DTT, 0.1% SDS, 0.5% deoxycholate, 1% Triton-X100, 20 mM b-glycerophosphate, 0.1 mM Na 3 VO 4 , 0.1 mM PMSF, 10 mg/ml leupeptin. The lysates were precleared with normal rabbit serum precoupled to Sepharose-protein A beads (1 h, 48C), then immunoprecipitation of JNK was performed with anti-JNK2 (FL, from Santa Cruz Biotechnology) precoupled to Sepharose-ProtA beads (overnight, 48C). The precipitates were washed four times with lysis buer and once with 20 mM HEPES pH 7.5. Kinase activity of the precipitates towards GST-cJun (1-79) fusion protein (kindly provided by Dr P Coer) was assayed in 30 ml of kinase buer (20 mM HEPES pH 7.5, 20 mM MgCl 2 , 2 mM DTT, 20 mM ATP (including 1 mCi [g-32 P]ATP), 0.5 mM NaF, 0.1 mM Na 3 VO 4 , 20 mM bglycerophosphate) supplemented with 4 mg GST-c-Jun protein. Samples were incubated for 20 min at 308C, reactions were stopped by adding SDS-sample buer and the samples were separated by SDS ± PAGE. The gel was ®xed, dried and analysed using a phospho-imager.
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